---
schema_version: "secwatch.filing_event.v1"
accession: "0001762303-25-000012"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:01:14.406810+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q2 revenue $18.4M (+21% YoY); slashes FY2025 revenue guidance to $76M-$81M, delays profitability to 2026

## Summary
- Q2 2025 commercial revenue $18.4M (+21% YoY); net loss $9.9M vs $15.4M prior year.
- FY2025 revenue guidance reduced to $76M-$81M (prior $100M-$106M) due to MAC payment backlog affecting RECELL demand.
- Fifth amendment to OrbiMed credit agreement: TTM revenue covenants lowered through Q2 2026; 400,000 common shares issued in lieu of cash fee.
- Michael Tarnoff appointed to Board of Directors; adds healthcare leadership experience.
- Clinical highlight: RECELL reduces hospital stays 36%; CMS NTAP approved for inpatient trauma wounds.

## SEC filing metadata
- accession: 0001762303-25-000012
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000176230325000012/0001762303-25-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000176230325000012/rcel-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001762303-25-000012
- JSON: https://secwatch.observer/filing/0001762303-25-000012.json
- Plain text: https://secwatch.observer/filing/0001762303-25-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.